spacer
home > ebr > summer 2003 > mass-based fraction collection of crude synthetic peptides in analytical and preparative scale for cancer treatment
PUBLICATIONS
European Biopharmaceutical Review

Mass-Based Fraction Collection of Crude Synthetic Peptides in Analytical and Preparative Scale for cancer treatment

Synthetic peptides become more and more important as drug candidates in the treatment of a variety of diseases. A particular therapeutic focus for synthetic peptides is cancer treatment (1, 2). In order to keep pace with the growing number of newly synthesised peptides, peptide purification should not represent a bottleneck in the drug discovery process. Since the target masses of synthetic peptides are well known, mass-based fraction collection represents an efficient technique for their purification. In contrast to fraction triggering with less specific detectors, employing a mass selective detector only leads to the purification of the target mass in each run. Consequently, it is not necessary to pick out the compound of interest from a series of redundant fractions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ralf Moritz, Application Chemist at Agilent Technologies, and Nicola O'Reilly at Cancer Research UK
Ralf Moritz studied Chemistry at Gerhard Mercator University, Germany, before moving to McMaster University in Canada for a year in 1993.

He completed his PhD thesis at Robert Koch-Institute, Berlin in 2000 before undertaking research work at the Max Delbrück Centrum for Molecular Medicine, Berlin. Since 2001 Ralf has been an Application Chemist at Agilent Technologies, Germany.


Nicola O'Reilly received a BSc (Hons) in Chemistry from Southampton University in 1987. She then joined Cancer Research UK (then Imperial Cancer Research Fund), running the peptide synthesis laboratory.

In 1994 Nicola completed a master's degree in Biochemistry at King's College London. In October 1999 she set up a new 2D gel electrophoresis facility and in July 2000 she took over the ICRF Protein Isolation Service. After the formation of Cancer Research UK she opened up peptide synthesis and protein isolation to new Cancer Research UK clients.


spacer
Ralf Moritz
spacer
spacer
spacer
Nicola O'Reilly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement